Paclitaxel remains first-line for cutaneous angiosarcoma, but absence of validated second-line therapy creates a major unmet ...
Almost 100% of patients with recurrent/metastatic endometrial cancer benefited from an investigational bispecific antibody ...
A combination of Verzenio and letrozole has shown encouraging and lasting responses in patients with advanced or recurrent ...
The 12-month PFS rate was 69.0% in the fruquintinib-sintilimab arm and 34.6% in the investigator’s choice arm. For patients with advanced or metastatic renal cell carcinoma (RCC), fruquintinib plus ...
Most patients initiated full-dose ibrutinib, while reduced starting doses clustered in older, more comorbid, poorer ECOG ...
Please provide your email address to receive an email when new articles are posted on . Women with advanced ovarian cancer derived significant quality-adjusted PFS benefit from niraparib compared with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results